KR20220062363A - 암 표적성 약물 전달체로서의 인지질 에테르 접합체 - Google Patents

암 표적성 약물 전달체로서의 인지질 에테르 접합체 Download PDF

Info

Publication number
KR20220062363A
KR20220062363A KR1020227011911A KR20227011911A KR20220062363A KR 20220062363 A KR20220062363 A KR 20220062363A KR 1020227011911 A KR1020227011911 A KR 1020227011911A KR 20227011911 A KR20227011911 A KR 20227011911A KR 20220062363 A KR20220062363 A KR 20220062363A
Authority
KR
South Korea
Prior art keywords
cancer
compound
pharmaceutically acceptable
melanoma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227011911A
Other languages
English (en)
Korean (ko)
Inventor
제로드 롱코르
애나토리 핀척
랜돌 후버
종핑 후앙
Original Assignee
셀렉타 바이오사이언시스, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀렉타 바이오사이언시스, 인코퍼레이티드 filed Critical 셀렉타 바이오사이언시스, 인코퍼레이티드
Publication of KR20220062363A publication Critical patent/KR20220062363A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020227011911A 2019-09-12 2020-09-11 암 표적성 약물 전달체로서의 인지질 에테르 접합체 Pending KR20220062363A (ko)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201962899611P 2019-09-12 2019-09-12
US201962899618P 2019-09-12 2019-09-12
US201962899615P 2019-09-12 2019-09-12
US62/899,615 2019-09-12
US62/899,611 2019-09-12
US62/899,618 2019-09-12
US201962946870P 2019-12-11 2019-12-11
US62/946,870 2019-12-11
US202062956844P 2020-01-03 2020-01-03
US202062956907P 2020-01-03 2020-01-03
US62/956,844 2020-01-03
US62/956,907 2020-01-03
PCT/US2020/050459 WO2021050917A1 (en) 2019-09-12 2020-09-11 Phospholipid ether conjugates as cancer-targeting drug vehicles

Publications (1)

Publication Number Publication Date
KR20220062363A true KR20220062363A (ko) 2022-05-16

Family

ID=74866023

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227011911A Pending KR20220062363A (ko) 2019-09-12 2020-09-11 암 표적성 약물 전달체로서의 인지질 에테르 접합체

Country Status (12)

Country Link
US (1) US20230066517A1 (https=)
EP (1) EP4028018A4 (https=)
JP (3) JP7749542B2 (https=)
KR (1) KR20220062363A (https=)
CN (1) CN114599371A (https=)
AU (1) AU2020346898B2 (https=)
BR (1) BR112022004482A2 (https=)
CA (1) CA3150991A1 (https=)
IL (1) IL291197A (https=)
MX (1) MX2022003044A (https=)
NZ (1) NZ786360A (https=)
WO (1) WO2021050917A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3095515A1 (en) * 2018-04-10 2019-10-17 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
NZ786360A (en) * 2019-09-12 2025-12-19 Cellectar Biosciences Inc Phospholipid ether conjugates as cancer-targeting drug vehicles
BR112022006739B1 (pt) * 2019-10-10 2024-01-23 Cellectar Biosciences, Inc Conjugados fosfolipídio-flavagina e métodos de uso do mesmo para terapia direcionada a câncer
CN113816990B (zh) * 2021-03-22 2023-08-22 联宁（苏州）生物制药有限公司 修饰的氨基酸及其在adc中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8540968B2 (en) * 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
WO2011031919A2 (en) * 2009-09-11 2011-03-17 Cellectar, Inc. Non-radioactive phospholipid compounds, compositions, and methods of use
CA2968145C (en) 2014-11-17 2023-06-27 Cellectar Biosciences, Inc. Phospholipid ether analogs as cancer-targeting drug vehicles
EP3439666A4 (en) 2016-05-20 2019-12-11 The University of Chicago NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ALL COMBINATIONS THEREOF
WO2017218702A1 (en) * 2016-06-14 2017-12-21 Cellectar Biosciences, Inc. Phospholipid ether analogs for the identification and isolation of circulating tumor cells
CA3095515A1 (en) 2018-04-10 2019-10-17 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
NZ786360A (en) * 2019-09-12 2025-12-19 Cellectar Biosciences Inc Phospholipid ether conjugates as cancer-targeting drug vehicles

Also Published As

Publication number Publication date
MX2022003044A (es) 2022-06-02
WO2021050917A1 (en) 2021-03-18
NZ786360A (en) 2025-12-19
EP4028018A4 (en) 2023-10-11
CN114599371A (zh) 2022-06-07
JP7749542B2 (ja) 2025-10-06
JP2025138792A (ja) 2025-09-25
IL291197A (en) 2022-05-01
JP2022547331A (ja) 2022-11-11
AU2020346898A1 (en) 2022-04-07
AU2020346898B2 (en) 2026-04-09
BR112022004482A2 (pt) 2022-05-31
JP2025087716A (ja) 2025-06-10
EP4028018A1 (en) 2022-07-20
CA3150991A1 (en) 2021-03-18
US20230066517A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
US11439709B2 (en) Phospholipid ether analogs as cancer-targeting drug vehicles
KR20220062363A (ko) 암 표적성 약물 전달체로서의 인지질 에테르 접합체
US20240009321A1 (en) Immunogenic nanovesicles for cancer immunotherapy
US12496346B2 (en) Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
WO2022235889A1 (en) Hsp90-binding conjugates and formulations thereof
CN121127460A (zh) 可用作治疗剂的新型化合物
EA053296B1 (ru) Конъюгаты простого эфира фосфолипида в качестве носителей лекарственного средства для нацеливания на рак
HK40075720A (en) Phospholipid ether conjugates as cancer-targeting drug vehicles
HK40042533A (en) Phospholipid ether analogs as cancer-targeting drug vehicles
EA047198B1 (ru) Конъюгаты фосфолипид-флаваглин и способы их применения для нацеленной противораковой терапии
HK40042533B (en) Phospholipid ether analogs as cancer-targeting drug vehicles
NZ731669B2 (en) Phospholipid ether analogs as cancer-targeting drug vehicles

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000